Loading stock data…
Gilead Sciences (GILD)
$127.88+4.04 (+3.26%)
Market ClosedLast close Jun 26
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Gilead Sciences, Inc. in the Healthcare sector is trading at $126.33 with a market capitalization of $157.6B. Wall Street consensus targets $157.57 (28 analysts), implying a +24.7% move over the next 12 months. The stock is currently 20% below its 52-week high of $157.29, remaining 1.5% below its 200-day moving average. On fundamentals, Piotroski 8/9 indicates strong financial quality, Altman Z in the safe zone. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +24.7% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $6.96B↓ | $7.92B↑ | $7.77B↑ | $7.08B↑ | $6.67B |
| Gross Profit | $5.51B↓ | $6.30B↑ | $6.20B↑ | $5.58B↑ | $5.13B |
| Operating Income | $2.69B↓ | $2.99B↓ | $3.50B↑ | $2.72B↑ | $2.49B |
| Net Income | $2.02B↓ | $2.18B↓ | $3.05B↑ | $1.96B↑ | $1.31B |
Peer Comparison
JNJUNHPFE
Fundamentals
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunl...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$157.64B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Strong income play. Yield provides a meaningful total return floor.
2.49%
ROE
Elite ROE. Management converts capital into profit efficiently.
39.19%
Volume
Today's trading volume
19.91M
Recent News
Gilead (GILD) Moves 3.3% Higher: Will This Strength Last?
Gilead (GILD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Gilead (GILD) Wins FDA Approval for Trodelvy in TNBC
Gilead Sciences, Inc. (NASDAQ:GILD) is one of the 12 Most Profitable S&P 500 Stocks to Invest In. On June 25, 2026, the Food and Drug Administration approved Trodelvy from Gilead Sciences, Inc. (NASDAQ:GILD) for two indications in adults with triple-negative breast cancer. The first approval covers sacituzumab govitecan-hziy as a single agent for the first-line […]
Will Trodelvy’s First-Line TNBC Approval Redefine Gilead Sciences’ (GILD) Oncology-Led Investment Narrative?
Earlier this week, Gilead Sciences received FDA approval for an expanded use of Trodelvy, authorizing it as a first-line treatment for adults with unresectable locally advanced or metastatic triple-negative breast cancer, either alone in PD-(L)1–ineligible patients or in combination with Keytruda for PD-L1–positive tumors. This decision, underpinned by robust Phase 3 ASCENT-03 and ASCENT-04 data and reinforced by top-tier NCCN guideline endorsements, elevates Trodelvy’s role in breast cancer...
Gilead Sciences (GILD) Wins First Line Trodelvy Approval In The US And Europe
FDA approved Gilead Sciences' (NasdaqGS:GILD) Trodelvy for first line treatment of metastatic triple negative breast cancer in the US. Regulators in Europe granted a similar first line approval, creating aligned indications across key markets. Decisions follow clinical data showing survival benefits for patients treated with the Trop 2 directed antibody drug conjugate. Gilead Sciences has been known largely for its antiviral portfolio, and Trodelvy adds further weight to its growing...
Ascendis Pharma (ASND) Moves 9.9% Higher: Will This Strength Last?
Ascendis Pharma (ASND) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.